Elrexfio Becomes Pfizer’s First Approved Multiple Myeloma Drug
XTalks
AUGUST 18, 2023
After Johnson & Johnson’s US Food and Drug Administration (FDA) approval last week for its second multiple myeloma bispecific, Talvey (talquetamab), Pfizer received an FDA nod for its B-cell maturation antigen (BCMA)-directed therapy Elrexfio (elranatamab) in the same indication.
Let's personalize your content